secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001213900-26-001790
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals director James W. Newman Jr. resigns from Board effective Jan 5, 2026
--------------------------------------------------------------------------------

- James W. Newman Jr. resigned as director and member of Audit and Compensation Committees, effective January 5, 2026.
- No disagreement with company operations, policies or practices cited.
- No replacement has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026001790/0001213900-26-001790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026001790/ea027192401-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-001790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer